Memo Therapeutics AG

Our CEO Erik van den Berg and CFO Lars Spenger will be attending Jefferies London Healthcare Conference 2024 from November 19-21. We look forward to connecting with industry leaders and investors as we continue progressing potravitug, our lead clinical asset, in the largest ever placebo controlled clinical trial for the treatment of BK viremia in kidney transplant recipients. If you're attending the conference and would like to learn more about our innovative antibody development programs, please get in touch at: info@memo-therapeutics.com. #JefferiesHealthcare #MemoTherapeuticsAG #MTx #Biotech #DrugDiscovery #Innovation #AntibodyDiscovery

Memo Therapeutics AG is delighted to announce the appointment of Frits van Alphen, MD as our new Chief Development Officer.   With over 30 years of international experience in clinical development and medical affairs, Frits brings valuable expertise in nephrology and rare diseases to our team.   Frits will drive the development of our lead asset, potravitug, which recently finished enrolment in a Phase II clinical trial targeting BK viremia in kidney transplant recipients. His proven track record in successfully leading late-stage drug development programs makes him an excellent fit as we become a Phase III ready organisation.   Read more about Frits’ appointment here: https://lnkd.in/eWJu6B77   #MemoTherapeuticsAG #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #Innovation #NewHire

We are pleased to report that the last patient has been enrolled in our 22-site U.S. Phase II trial for BK viremia in kidney transplant patients – the largest placebo-controlled trial ever conducted for this disease.  With a significant unmet clinical need for BK polyomavirus associated nephropathy (#BKVAN), we look forward to advancing potravitug through clinical development and help transform the lives of kidney transplant patients worldwide. Read more about the ongoing Phase II trial here: https://lnkd.in/eWCGGcJw #MemoTherapeuticsAG #MTx #AntibodyDiscovery #Nephrology #DrugDiscovery #Innovation #ClinicalTrial

Our CFO Lars Spenger and VP Commercial Strategy, Alexander Bastian are attending the 30th annual #BIOEurope conference in Stockholm, Sweden from 4-6 November.   As our Phase II clinical trial progresses for potravitug, our lead asset targeting BK viremia in kidney transplant patients, we are looking forward to connecting with industry leaders and investors as we prepare to become a Phase III ready organization.   Find the full conference agenda here: https://lnkd.in/dnuNZ2D   #BIOEurope #Networking #30years #MemoTherapeuticsAG #MTx #Biotech

Our goal is to transform the lives of patients with viral infections and cancer by developing best-in-class therapeutic antibodies, therefore patients are at the core of our work and #research.   Meet Kevin Fowler our patient advocate consultant and Principal of ‘The Voice of the Patient’, a patient advocacy and engagement consulting business.   In this #spotlight Q&A, Kevin takes us through his personal journey with kidney disease, how it led to his involvement in patient advocacy and the important role that biotech companies have in properly catering to the needs of kidney disease patients.   Flip through the full Q&A below or on our website here: https://lnkd.in/ejnt2UzZ   #EmployeeSpotlight #AntibodyDiscovery #BiotechInnovation #BehindTheScenes #MemoTherapeuticsAG #MTx #Biotech

We will be presenting a poster in collaboration with Maja Kuharic from Northwestern University and Kevin Fowler on the burden of BK polyomavirus infection in kidney transplant recipients at the Annual American Society of Nephrology #ASNKidney Meeting in San Diego, California, USA.   Our CEO, Erik van den Berg, CMO, Juergen Beck, VP Commercial Strategy, Alexander Bastian and VP Clinical Operations, Kristie Bass Clemmer will be in attendance.   Poster title: Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research Date: October 26, 2024 | 10:00 AM Location: Exhibit Hall, Convention Center   Learn more about our work in developing best-in-class therapeutic antibodies for viral infections and cancer here: https://lnkd.in/ebCsH5TM   #KidneyWeek #KidneyDisease #MemoTherapeuticsAG #MTx #AntibodyDiscovery #Nephrology #DrugDiscovery #Innovation

Our CFO, Lars Spenger will be at Sachs Associates Annual Biotech in Europe Forum in Basel, Switzerland.   On the back of a recent series C extension of CHF 20 million and several new additions to our management team, we are rapidly becoming a Phase III ready organization with our lead asset, potravitug, currently in a Phase II clinical trial.   If you would like to speak to Lars, please contact us at: info@memo-therapeutics.com. #MemoTherapeuticsAG #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #Cancer #Innovation #VentureCapital #Partnering

We are proud to have a talented team who are driven by a common purpose to transform the lives of patients with viral infections and cancer through best-in-class therapeutic antibodies.   Meet Matthieu Delincé, our Director of Oncology Research, who is spearheading Memo Therapeutics AG’s efforts to improve cancer treatments. In this #spotlight Q&A, we delve into Matthieu’s background and how he and his team use our proprietary DROPZYLLA® technology to identify novel antibody-target pairs for the treatment of solid tumours.   Read the full Q&A here: https://lnkd.in/eB2iia6s    #EmployeeSpotlight #AntibodyDiscovery #BiotechInnovation #BehindTheScenes #MemoTherapeuticsAG #MTx #Biotech 

The Memo Therapeutics AG team, Erik van den Berg, Alexander Bastian and Matthieu Delincé will be present at ESMO - European Society for Medical Oncology Congress 2024 from 13-17 September in Barcelona Spain.   Join us in Barcelona as we engage in meaningful discussions and explore innovative solutions. We are currently using our proprietary DROPZYLLA® discovery platform to identify antibodies in elite patients to develop targeted cancer therapies.   Find the full agenda for the congress here: https://lnkd.in/eytECTz8   #ESMO2024 #MemoTherapeuticsAG #MTx #AntibodyDiscovery #Oncology #DrugDiscovery #Innovation  

Our CEO Erik van den Berg has been featured on the latest #BusinessOfBiotech #podcast with Matthew Pillar!   With approaching 30 years of experience embracing the chaos of #biotech, Erik offers invaluable insights into navigating our dynamic industry, including keeping development on track through bull and bear markets and creating differentiation in crowded therapeutic spaces.   Tune in to hear how Memo Therapeutics AG is charting its course through the exciting, ever-changing biotech landscape on YouTube here: https://lnkd.in/e4HCTA-S    Also available on Spotify/Apple podcasts: https://lnkd.in/ejkdutGC   #Leadership #MemoTherapeuticsAG #AntibodyDiscovery #BiotechInnovation